The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.

doi:10.1016/j.prp.2022.154147

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.

Pathology, research and practice - 1 Nov 2022

Ulusan Murat, Sen Sena, Yilmazer Rasim, Dalay Nejat, Demokan Semra

Abstract excerpt

BACKGROUND: The let-7 family of microRNAs regulate multiple oncogenes including the KRAS gene and has been shown to play a critical role in carcinogenesis. In this study, we aimed to investigate polymorphic alterations of the let-7 miRNA binding site (rs61764370) in the 3'UTR region of the KRAS gene as a predictive biomarker for head and neck cancer (HNC) and to evaluate its association with clinicopathological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Binding Sites

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Colorectal Neoplasms

Share to Head and Neck Neoplasms

Share to Lymphatic Metastasis

Share to MicroRNAs

Share to Polymorphism, Single Nucleotide

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed

Identifiers

PMID: 36228348
DOI: 10.1016/j.prp.2022.154147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.PMID 36228348Read ↗

Evaluation of the simultaneous effects of KRAS G12V and LCS6 alterations on the behavior of head and neck squamous cell carcinoma.Semantic proximity Read ↗

A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.Semantic proximity Read ↗

Association of Rs61764370 polymorphism within let-7 microRNA-binding site with lung cancer in Iranian population.Semantic proximity Read ↗

Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma.Semantic proximity Read ↗

Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.Semantic proximity Read ↗

A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.Semantic proximity Read ↗

Investigation of Combined Effects of KRAS-G12V and KRAS- 2 LCS6 (rs61764370) Alterations on Tumor Progression and Me- 3 tastasis in HNSCC by Using Xenograft Mouse ModelSemantic proximity Read ↗

A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.Semantic proximity Read ↗

Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patientsSemantic proximity Read ↗

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.Semantic proximity Read ↗

A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.Semantic proximity Read ↗

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.